Real Heart (HEART) - Total Liabilities
Based on the latest financial reports, Real Heart (HEART) has total liabilities worth Skr13.59 Million SEK (≈ $1.46 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Real Heart cash flow conversion to assess how effectively this company generates cash.
Real Heart - Total Liabilities Trend (2010–2024)
This chart illustrates how Real Heart's total liabilities have evolved over time, based on quarterly financial data. See HEART total equity for net asset value and shareholders' equity analysis.
Real Heart Competitors by Total Liabilities
The table below lists competitors of Real Heart ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Titan Logix Corp.
V:TLA
|
Canada | CA$1.21 Million |
|
Entero Therapeutics, Inc.
NASDAQ:ENTO
|
USA | $45.81 Million |
|
Perfect Moment Ltd.
NYSE MKT:PMNT
|
USA | $12.74 Million |
|
P3 Health Partners Inc
NASDAQ:PIII
|
USA | $664.64 Million |
|
Akkhie Prakarn Public Company Limited
BK:AKP
|
Thailand | ฿92.21 Million |
|
CD Private Equity Fund I
AU:CD1
|
Australia | AU$633.01K |
|
Thai Wire Products Public Company Limited
BK:TWP
|
Thailand | ฿462.44 Million |
|
Jaya Trishindo Tbk PT
JK:HELI
|
Indonesia | Rp119.97 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down Real Heart's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Real Heart worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Real Heart's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Real Heart (2010–2024)
The table below shows the annual total liabilities of Real Heart from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr15.94 Million ≈ $1.72 Million |
-22.62% |
| 2023-12-31 | Skr20.60 Million ≈ $2.22 Million |
-7.08% |
| 2022-12-31 | Skr22.17 Million ≈ $2.39 Million |
+239.78% |
| 2021-12-31 | Skr6.53 Million ≈ $702.20K |
+2.75% |
| 2020-12-31 | Skr6.35 Million ≈ $683.39K |
-16.57% |
| 2019-12-31 | Skr7.61 Million ≈ $819.12K |
-6.31% |
| 2018-12-31 | Skr8.12 Million ≈ $874.25K |
+26.15% |
| 2017-12-31 | Skr6.44 Million ≈ $693.01K |
+60.72% |
| 2016-12-31 | Skr4.01 Million ≈ $431.18K |
+534.12% |
| 2015-12-31 | Skr631.85K ≈ $68.00K |
-26.28% |
| 2014-12-31 | Skr857.12K ≈ $92.24K |
+1.78% |
| 2013-12-31 | Skr842.11K ≈ $90.62K |
+91.93% |
| 2012-12-31 | Skr438.75K ≈ $47.22K |
+613.58% |
| 2011-12-31 | Skr61.49K ≈ $6.62K |
-15.36% |
| 2010-12-31 | Skr72.65K ≈ $7.82K |
-- |
About Real Heart
Scandinavian Real Heart AB (Publ) engages in the design and development of an artificial heart. The company develops Realheart TAH to treat advanced stage heart failure. It also develops RealVAD for pulsating left ventricle assist; PulsePump, a pulsating flow for heart and lung machines; and Sternal Prosthesis to fix the sternum after open-chest surgery. The company was founded in 1999 and is bas… Read more